Immunotherapeutics – A New Tool to Address Immune Related Illness
Meditrend was founded in 1984 to commercialize innovative health solutions. Our goal is to discover, develop and distribute medically sound, economically viable products and services that improve the quality of health.
After over 100 years of immunotherapeutic research, promising approaches in modern treatment of immune related illness are now available. These methods augment and enhance the body’s natural tendency to defend against allergenic substances and abnormal cells without damaging tissue or internal organs.
Richard D. Savage. Founder
Injectable Immunotherapy and VitaleGENx for Immune Related Illness
VitaleGENx – our subcutaneous injectable remedy, stimulates humoral immune response for cancer and immune related illness. This broad spectrum immunotherapeutic is composed of substances synthetically derived from Vitaletheine, a family of biochemical modulators discovered by university researchers to regulate immunity.
Vitaletheine was reported in two back-to-back articles of Cancer Research, an international peer reviewed medical journal. Studies partially funded by the National Institutes of Health evidence regulation of humoral immune response. These broad spectrum immuno-modulators stimulate surveillance of deviant cell production and amplify or suppress natural immune response to light infection and process abnormal cells … naturally.
After over 100 years of immunotherapeutic research, promising approaches in modern treatment of immune related illness are now available to stimulate natural immune response. These methods augment and enhance the body’s natural tendency to defend itself against abnormal cells without damaging tissue.
The Vitaletheine Modulators are a family of biochemically related regulatory factors of immunity discovered by university researchers. The organic chemical compound of Vitaletheine is made naturally in mammals from L-Cysteine and D-pantothenic acid. Deficiencies of Vitaletheine may result from malnourishment, metabolic imbalances and environmental poisoning.
Scientists synthetically derived substances of Vitalethine for use in animal studies. Outcomes in mice models reported in back to back articles by Cancer Research an international, peer reviewed medical journal evidence humoral immunity is an antibody-mediated process absolutely dependent upon the Vitaletheine Modulators, and largely responsible for the dramatic responses observed.
A distributed center proving to determine the “indications of use” for synthetically derived substances of Vitalethine have been homeopathically prepared for injection in humans and animals by Meditrend under the trade name VitaleGENx. Available by prescription only, licensed medical professionals or veterinarians can currently prescribe VitaleGENx for physician or self-injection.
The homeotherapeutic protocol for VitaleGENx includes proprietary nutritional formulations that provide:
- building blocks essential to production and utilization of vitalethine
- removal of environmental pollutants that prevent proper function of the Vitaletheine Modulators and
- balance numerous metabolic pathways without poisoning natural Vitaletheine.
INJECTABLE HOMEOPATHIC – Broad Spectrum Immune Modulation and Surveillance
For individuals or animals whose immune response is suppressed or limiting or restricting their ability to form antibodies Cysteinum HPUS and Coenzyme A HPUS Derived Complex.
Immunotherapeutic methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors and aberrant cells without damaging tissue are promising new approaches for modern treatment of immune related illness. University researchers under a partial grant from the National Institute of Health discovered a family of biochemical substances called the Vitaletheine Modulators that appear to modulate cholesterol production, glucose metabolism, and humoral immunity. Back-to-back publications in a prominent international, peer-reviewed medical journal evidenced beneficial outcomes in animal models inoculated with S-91 melanoma and NS-1 myeloma when treated with synthetically derived preparations of these biochemical substances (See Abstracts attached). The thiol form, Vitaletheine (sic., VS-H) and its disulfide Vitalethine (sic., VS-SV) are made naturally in the body from a thiol containing amino acid (L-cysteine) and vitamin B5 (D-pantothenic acid). A thiol is anorganic chemistry compound (R) containing the functional group comprised of a sulfur atom and a hydrogen atom (e.g., R-SH). Deficiencies of Vitaletheine and Vitalethine result from malnourishment, metabolic imbalances, and environmental poisoning.
Importantly, all current data indicate the humoral immune system is an antibody- mediated process that can be absolutely dependent upon the Vitaletheine Modulators, the same process that appears largely responsible for dramatic therapeutic responses observed in the mice study models. Similar human responses can be anticipated based upon studies using white blood cells of the immune system (sic., leukocytes) that help protect both mice and humans from cancer, infectious disease and even invasive foreign entities. Biological responses of human peripheral blood leukocytes are virtually identical to those of mouse spleen leukocytes (splenocytes) when treated with Vitalethine or selected, structurally related compounds.
Synthetically derived preparations of these biochemical substances that occur naturally in all mammals have been identified and well-characterized by IR, NMR and Mass Spectra. A liquid attenuation complex of these soluble substances derived from Coenzyme A and Cysteinum, both “official” listed ingredients in the Homeopathic Pharmacopeia of the United States (HPUS), have been prepared under homeopathic conditions and the monograph name, VitaleGENx, which induce the formation of antibodies. The preparation resembles and delivers natural metabolites (of L-cysteine, 4’-phosphopantothenylated cysteine, of 4’-phosphopantethieine), and of coenzyme A (e.g. VSOH) from a chemical complex of carbobenzoxy-blocked beta-alanine (“CBZ-ß-alanine” that is otherwise bio-identical to ß-alanine) and of cysteamine which also occurs naturally in mammals.
Sequential splitting of the bonds in vitalethine with water (hydrolysis), from left to right at the positions indicated by dotted lines, results in i) carbonic acid (H2CO3) and the mixed disulfide of beta-aletheine and vitaletheine, ii) beta-alanine and the mixed disulfide of cysteamine and vitaletheine, and iii) either cysteamine and the sulfenic acid of vitaletheine or the sulfenic acid of cystamine and vitaletheine. The hydrogen (H) of water usually binds to nitrogen (N) and the (-OH) usually binds to the carbonyl (-C=O) of the carbamic acid or amid [-C(=O)-N-] groups being hydrolyzed.
Reduction of the central disulfide vitaletheine, and with sequential hydrolysis of this reduced form, beta-aletheine and cysteamine. Reduced forms are variously known as thiols, sulfides, sulfhydryls, and sulphydryls.
TECHNICAL DESCRIPTION AND INSTRUCTIONS FOR USE
To be used on advice and supervision of a medical physician or a homeopathic health care practitioner licensed
to prescribe and administer injections. This homeopathic dilution resembles and delivers the activated form of natural Vitalethine.
Must be custom diluted for individual patients.
Indications Of Use:
For use in the treatment of humoral immune suppression and antibody production deficiencies, for biosynthesis and regulation of thyroid hormone activation, or to normalize hypoglycemia, hyperglycemia, and hypercholesterolemia or hypocholesterolemia.
Composition:
Custom-prepared homeopathic injectable preparations for subcutaneous administration.
Medicinal Ingredients:
A derivative complex of Cysteinum HPUS and Co-Enzyme A in sterile physiological saline.
Dosage Form:
Glass, sealed vials of bulk, sterile homeopathic dilutions of formulation are provided in physiological saline to compounding pharmacies for individualized subcutaneous injection by syringe.
Distributor:
Meditrend, Inc. Albuquerque, NM 87111
Contra-Indications:
– Since precipitous die-off of cancer cells can poison immune
– responses, patients undergoing radiation or chemotherapy should
not be treated with VitaleGENx until all such therapy protocols
have ended.
– DO NOT USE VitaleGENx homeopathic immune support if you are
an organ transplant patient.
– Avoid use of cimetidine (Tagamet®).
– Avoid use of ranitidine (Zantac®).
– Do Not Administer VitaleGENx more frequently than once every 10
days.
– VitaleGENx should not be mixed with any kind of alcohol,
especially isopropanol, ethanol, or methanol.
– Allow skin prepared with sterilizing pad to dry prior to injection.
Cautions And Warnings:
Patients considering treatment with any immune support, including homeopathic VitaleGENx, should have their symptoms
and indications of use identified and monitored by practitioners in accordance with the prescribed VitaleGENx homeotherapeutic
protocol.
Patients using Cisplatin or therapies containing other toxic metals, alkylating chemotherapeutic agents, anti-inflammatory steroids or other thiol- or sulfenate-depleting chemicals or preservatives, or who are currently undergoing intense radiation or other immune
suppressive treatments are not good candidates for humoral immune support with VitaleGENx.
Additional nutritional and environmental support is essential for optimal response.
Precautions:
Sulphur-vulcanized rubber and siliconized plungers, vials and septa have not been evaluated systematically for reliable use with this preparation.
Interactions:
The VitaleGENx chemistry is well-defined, however, interactions with other drugs and medicines have not been thoroughly investigated.
Pregnancy And Lactation:
Do not use if pregnant or breastfeeding. Although the Vitaletheine Modulators have been shown to stabilize healthy cells in culture, safety in pregnancy and while breast feeding has not been evaluated. Rh blood factors when the father and fetus are Rh-positive and the mother is Rh-negative mother can complicate immune supportive approaches.
Effects On Driving Ability Or The Use Of Machines:
No know effects.
Dosage:
The homeotherapeutic protocol for VitaleGENx is:
• Dosage optimum (~100 picograms/kg body weight)
• Therapeutic for 1-3 years (Suggested injection once every 10 days)
• Maintenance thereafter (Suggested Injection once every 14 days)
Conditions of Use-Homeopathic immune support should be undertaken when specific indications of use have been identified by a medical physician or homeopathic health care practitioner licensed to administer injectible preparations.
Age-Treatment may be commenced after age 3, which approximates efficacy studies in weanling mice.
Known Adverse Events- Advanced cancers can elicit aggressive immune responses. Do Not Use VitaleGENx while undergoing radiation or chemotherapy. It is likely that precipitous die-off will render immune support with VitaleGENx far less effective.
Method Of Administration:
Subcutaneous Injection: Ensure all air bubbles are removed from the sterile syringe drawn with the sterile individualized dilution. Sterilize skin of lower abdomen and allow skin to dry prior to injecting contents (from drawn, bubble-free syringe) into pinched skin of sterilized injection site. The homeotherapeutic protocol has
been established in controlled animal studies. DO NOT ADMINISTER VitaleGENx more frequently than once every 10 days.
Reference:
-Knight, G.D., Laubscher, K.H., Fore, M.L., Clark, D.A., and Scallen, T.J. Vitalethine modulates erythropoiesis and neoplasia. Cancer Res., 54:
5623-5635, 1994.
-Knight, G.D., Mann, P.L., Laubscher, K.H., and Scallen, T.J. Seemingly diverse activities of beta-alethine. Cancer Res., 54: 5636-5642, 1994.
References:
Cancer Research
The Journal of Cancer Research (1916-1930) | The American Journal of Cancer (1931-1940)
[CANCER RESEARCH 54, 5636-5642, November 1, 1994]
Seemingly Diverse Activities of β-Alethine1
Galen D. Knight, Paul L. Mann, Kevin H. Laubscher, and Terence J. Scallen2
School of Medicine [G. D. K., K. H. L., T. J. S.] and College of Pharmacy [P. L. M.], University of New Mexico, Albuquerque, New
Mexico 87131
ABSTRACT
β-Alethine (β-alanyl-cysteamine disulfide) exhibits striking biological activities in diverse systems. At an optimum of about 10 ng/ml,
β-alethine (a) adapts murine liver cells to culture (53 colonies/106 cells versus none in controls), (b) delays aging of human IMR-90 fetal lung fibroblasts (102 population doubling levels versus 47 in controls, producing 3 × 1016 greater biomass), and (c) markedly stimulates antibody-producing plaque-forming cells from murine splenocytes (16,875/106 cells versus 55/106 cells in controls) or human peripheral blood leukocytes (1826/106 cells versus 0/106 cells in controls). Early interventions with β-alethine (1 ng/kg to 100
μg/kg) successfully treat NS-1 myeloma in a syngeneic murine tumor model (NS-1 myeloma). Although there are indications in this
model that β-alethine is also effective when intervention is late, β-alethine is ineffective in an allogeneic murine melanoma model (Cloudman S-91 melanoma). It is inferred that β-alethine enhances cellular phenotypic expression, function, and vitality in diverse biological systems and may treat certain types of neoplasia. Because atomic spacings between the amide moieties in β-alethine are the same as in the differentiating agent hexamethylene-bis-acetamide and because the radioprotectors WR 2721 and WR 1065 lack only the carbonyl oxygen of the thiol form (β-aletheine), biological activities already reported for these compounds are compared with those presented herein for β-alethine. Although these comparisons have not been made in the same systems, the tentative conclusion is that the amide moieties of β-alethine may be critical to its potency and lack of obvious toxicity in cell culture and animal models.
http://cancerres.aacrjournals.org/content/54/21/5636.abstract
[CANCER RESEARCH 54, 5623-5635, November 1, 1994]
Vitalethine Modulates Erythropoiesis and Neoplasia1
Galen D. Knight,2 Kevin H. Laubscher, Marilyn L. Fore, Douglas A. Clark, and Terence J. Scallen
School of Medicine, University of New Mexico, Albuquerque, New Mexico 87131 [G. D. K., K. H. L., M. L. F., T. J. S.], and Department of Medicine, Veterans Administration Medical Center, Albuquerque, New Mexico 87108 [D. A. C.]
ABSTRACT
Novel compounds based upon the thiol N-(carboxy)-β-alanyl-cysteamine (vitaletheine) have strikingly potent and seemingly diverse biological activities. Concentrations of vitaletheine modulators from 1 femtograms/ml to 100 picograms/ml medium regulate RBC production from progenitors initially deprived of erythropoietin. Similarly, as little as attograms/ml concentrations of the disulfide vitalethine stimulate immunological responses of murine splenocytes toward sheep RBC in a hemolytic plaque assay. Because dosages of vitalethine as low as femtograms/kg substantially diminish tumor size and incidence and increase survival to 80% in mice inoculated with a uniformly fatal melanoma (Cloudman S-91), activities of these compounds have in vivo significance. A preliminary probe of the benzyl derivative of vitalethine in a myeloma model (NS-1) suggests efficacy (100% survival) as well. The high potencies of the vitaletheine modulators, both in cell culture and in vivo, indicate that these or similar regulatory components, if constitutively present, probably occur endogenously at vanishingly small concentrations and may be prone to deficiency resulting from metabolic imbalances, irradiation, aging, diet, pathogenic or parasitic infections, or exposure to environmental pollutants. Pathways for the biosynthesis of vitaletheine are proposed and chemical syntheses of the vitaletheine modulators are described. Possible molecular mechanisms of action, including interactions with peptidyl hormones, other endogenous effectors, and xenobiotic and pharmaceutical compounds, are explored. Indications for the treatment of other diseases are identified.
http://cancerres.aacrjournals.org/content/54/21/5623.abstract
